---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-26-000142"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2026-07-30T20:03:41+00:00"
generated_at: "2026-07-30T20:05:15.323506+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DexCom Q2 2026 revenue up 13% to $1.308B; raises FY2026 guidance

## Summary
- Revenue $1.308B (+13% YoY); U.S. +11%, international +19% reported.
- GAAP EPS $0.64; non-GAAP EPS $0.70; GAAP operating margin 24.3% (+590 bps YoY).
- Raises FY2026 revenue guidance to $5.18-5.25B (11-13% growth); raises non-GAAP operating margin to ~23.5-24%.
- CONNECT trial shows CGM improves glucose control in type 2 diabetes not on insulin; Stelo app launched with AI insights.
- Cash $1.95B; revolving credit undrawn.

## SEC filing metadata
- accession: 0001093557-26-000142
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2026-07-30T20:03:41+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/0001093557-26-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/dxcm-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-26-000142
- JSON: https://secwatch.observer/filing/0001093557-26-000142.json
- Plain text: https://secwatch.observer/filing/0001093557-26-000142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.